MobbleOpen in Mobble ⇢
Health · Drug development · published 2026-08-29 · via MedPage Today

Milvexian Fails to Cut Recurrent Events in ACS, Safety Profile Holds

Image via MedPage Today
Image via MedPage Today

In the LIBREXIA ACS trial, milvexian did not reduce the composite of cardiovascular death, myocardial infarction, or ischemic stroke compared with placebo in patients with recent acute coronary syndrome on antiplatelet therapy. The trial was halted early for futility, but the drug did not increase major bleeding. The safety finding is reassuring for ongoing trials of milvexian in atrial fibrillation and stroke prevention.

Expanded Detail

EXPANDED:

The trial enrolled patients within seven days of an ACS event, with 92% undergoing revascularization and most receiving prolonged dual antiplatelet therapy. Median follow-up lasted 12.2 months. The data and safety monitoring board halted enrollment in November 2025 after determining the primary endpoint was unlikely to be met.

Milvexian's safety profile remains relevant because the drug is still being tested in two ongoing phase III programs: LIBREXIA AF for atrial fibrillation and LIBREXIA STROKE for secondary stroke prevention. The DSMB recommended those trials continue as planned, with results expected in 2026. A related factor XIa inhibitor, asundexian

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at MedPage Today →
Related stories
Life Biosciences reports early glaucoma injection results for reprogramming drug · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Factor XIa Inhibitor Shows No Benefit After Acute Coronary Syndrome.” Browse more stories.